Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA

NodeGuardian · 2026-03-14T05:39:37+00:00

Royce & Associates LP raised its stake in Entrada Therapeutics by 54.8%, now holding shares worth $2,004,000. Institutional ownership is at 86.39%, with analysts maintaining a "Moderate Buy" rating and a target price of $18.50.

NodeGuardian

2026-03-14 05:39:37

إنشاء الملخص قيد التقدم

Royce & Associates LP increased its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 54.8% in Q3, now owning 345,507 shares valued at $2,004,000. Other institutional investors have also adjusted their holdings, with institutional ownership now at 86.39%. Despite some negative sentiment regarding earnings forecasts, analysts have a “Moderate Buy” rating for Entrada Therapeutics with a consensus target price of $18.50.

قد تحتوي هذه الصفحة على محتوى من جهات خارجية، يتم تقديمه لأغراض إعلامية فقط (وليس كإقرارات/ضمانات)، ولا ينبغي اعتباره موافقة على آرائه من قبل Gate، ولا بمثابة نصيحة مالية أو مهنية. انظر إلى إخلاء المسؤولية للحصول على التفاصيل.